EntoPharm aggressively and continuously searches for new drug candidates derived from insect immune systems. The following table provides a brief overview of the Company's product pipelines. Second to Alloferon, S2 is EntoPharm's most advanced prospective drug candidate.
 
Product
Indication
Property
Development Stage
Polyfensin
 Immunomodulatory
& Antimicrobial
agent 		· Group of Peptides
purified from insect
(C. vicina)
Completed
preclinical trial.
Alloferon
(S1)
 Immunomodulatory
agent (Antiviral
Anticancer)		 · Oligo peptide
identified & fractionated
from Polyfensin
· Chemically synthesized.
Phase II clinical
trial is going on.
S2
 Anticancer · Chemically engineered
peptides
Preclinical trial
(in vitro & in vivo)
S3
 Antibiotics · Recently identified
In vitro
S4
 Immune
booster		 · Recently identified
In vitro